title: Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study.
abstract: This trial investigated the tolerability and effect of modified citrus pectin (Pecta-Sol) in 13 men with prostate cancer and biochemical prostate-specific antigen (PSA) failure after localized treatment, that is, radical prostatectomy, radiation, or cryosurgery. A total of 13 men were evaluated for tolerability and 10 for efficacy. Changes in the prostate-specific antigen doubling time (PSADT) of the 10 men were the primary end point in the study. We found that the PSADT increased (P-value<0.05) in seven (70%) of 10 men after taking MCP for 12 months compared to before taking MCP. This study suggests that MCP may lengthen the PSADT in men with recurrent prostate cancer.
authors.affiliation: Prostate Oncology Specialist, Marina del Rey, California 90292, USA. Brad@prost8cancer.com
authors.forename: B W
authors.initials: BW
authors.lastname: Guess
authors.forename: M C
authors.initials: MC
authors.lastname: Scholz
authors.forename: S B
authors.initials: SB
authors.lastname: Strum
authors.forename: R Y
authors.initials: RY
authors.lastname: Lam
authors.forename: H J
authors.initials: HJ
authors.lastname: Johnson
authors.forename: R I
authors.initials: RI
authors.lastname: Jennrich
mesh_terms: D000368:Aged; D002957:Citrus; D006801:Humans; D008297:Male; D008875:Middle Aged; D010368:Pectins / Q000009:adverse effects / Q000737:chemistry* / Q000627:therapeutic use*; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood*; D013739:Testosterone / Q000097:blood
chemical_list: D013739:Testosterone; D010368:Pectins; D017430:Prostate-Specific Antigen